Delayed Selective Sentinel Node Biopsy for Patients Undergoing Mastectomy for DCIS

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Jun 12, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new approach for patients with ductal carcinoma in situ (DCIS) who are undergoing mastectomy, a surgery to remove breast tissue. Instead of removing the sentinel lymph node—the first lymph node that cancer cells are likely to spread to—during the initial surgery, doctors will mark it for later identification. If further testing shows that invasive cancer is present, a follow-up surgery will be done to remove that marked sentinel lymph node. The main goal of the trial is to see how successful this method is in identifying the sentinel lymph node when invasive cancer is confirmed.

To be eligible for this trial, participants should be between 20 and 75 years old, diagnosed with DCIS, and scheduled for a mastectomy. However, individuals with certain conditions, such as signs of invasive cancer from initial tests or previous lymph node surgery on the same side, will not be included. Those who join the study can expect to have their sentinel lymph node marked during their mastectomy, and if needed, they may have a second surgery to remove it later. This trial is currently recruiting participants of any gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 20 to 75 years old.
• • Patients diagnosed with DCIS through histological examination.
• • Patients undergoing mastectomy
• Exclusion Criteria:
• • In cases where the histopathological findings of the tissue examination indicate suspicious invasive lesions.
• • In cases where imaging tests or physical examinations suggest possible lymph node metastasis.
• • In patients who have previously undergone axillary lymph node surgery on the same side as the current procedure.
• • Pregnant patients.